Search
Thiacloprid
go.drugbank.com/drugs/DB08620ExperimentalCategories: Compounds used in a research, industrial, or household settingImolamine
go.drugbank.com/drugs/DB09284InvestigationalImolamine is a compound with a molecular weight of 260.33 g/mol with the formula diethyl[2-{5-imino-3-phenyl-4,5-dihydro-1,2,3-oxadiazol,-4-yl)ethyl]amine. It is developed under the brand name Coremax by Novartis consumer health SA.
Categories: Vasodilators Used in Cardiac DiseasesCitrulline
go.drugbank.com/drugs/DB00155InvestigationalNutraceuticalCitrulline is an amino acid. It is made from ornithine and carbamoyl phosphate in one of the central reactions in the urea cycle.
Synonyms: N(delta)-Carbamylornithine, N(5)-(Aminocarbonyl)-L-ornithineOxibendazole
go.drugbank.com/drugs/DB04910ExperimentalVet approvedOxibendazole is a polymerase inhibitor in phase III trials for the treatment of helminth intestinal infections.
Synonyms: Methyl 5-n-propoxy-2-benzimidazole carbamateDDP-200
go.drugbank.com/drugs/DB05919ExperimentalDDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia
INGN 225
go.drugbank.com/drugs/DB05325InvestigationalINGN 225 is currently in Phase 1/2 trials in patients with small cell lung cancer and breast cancer. … INGN 225 is a therapeutic consisting of a cancer patient's own immune cells treated with an adenovector carrying the human p53 gene, Ad-p53.
INCB13739
go.drugbank.com/drugs/DB05064InvestigationalIt is an orally available small molecule inhibitor of 11beta-HSD1 (11-beta hydroxysteroid dehydrogenase type 1). 11beta-HSD1 is an enzyme that appears to be critical to the development of type 2 diabetes
AT-301
go.drugbank.com/drugs/DB16507InvestigationalAT-301 was under investigation in clinical trial NCT01675284 to evaluate the safety, reactogenicity, and humoral immune responses to an inactivated H5N1 influenza vaccine
S-8510
go.drugbank.com/drugs/DB06504ExperimentalS-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.